GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » Profitability Rank

Novelion Therapeutics (STU:QLTA) Profitability Rank : 0 (As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics Profitability Rank?

Novelion Therapeutics has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Novelion Therapeutics's Operating Margin % for the quarter that ended in Mar. 2019 was -49.65%. As of today, Novelion Therapeutics's Piotroski F-Score is 0.


Competitive Comparison of Novelion Therapeutics's Profitability Rank

For the Biotechnology subindustry, Novelion Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novelion Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's Profitability Rank falls into.



Novelion Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Novelion Therapeutics has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Novelion Therapeutics's Operating Margin % for the quarter that ended in Mar. 2019 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2019 ) / Revenue (Q: Mar. 2019 )
=-14.149 / 28.497
=-49.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Novelion Therapeutics has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Novelion Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Novelion Therapeutics (STU:QLTA) Business Description

Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.